Treatment of metastatic penile cancer in the adjuvant setting with ifosfamide, paclitaxel, and cisplatin: A single institution experience.

Abstract

340 Background: Surgery alone rarely results in long-term disease-free control in patients with N2 or N3 (stage III or IV) metastatic penile cancer. Five-year overall survival rarely exceeds 40% in this group of patients. Ifosfamide, paclitaxel, and cisplatin chemotherapy (ITP) has been reported in the neoadjuvant setting in a phase II trial. The evidence supporting adjuvant chemotherapy after inguinal lymph node dissection (LND) is poor. We report our experience of ITP chemotherapy given in the adjuvant setting after bilateral inguinal LND for stage III and IV penile cancer Methods: In our regional cancer center we performed a retrospective analysis of a prospectively maintained database of all patients between May 2008 and February 2012 who received adjuvant chemotherapy for regional metastatic penile cancer. Results: Four patients received chemotherapy in the adjuvant setting. One patient completed 4 cycles of cisplatin and 5-Fluorouracil after bilateral inguinal LND (pT1N2). There is no evidence of disease recurrence at 20 months post completion of chemotherapy. Three patients received adjuvant chemotherapy with paclitaxel 175 mg/m2 on day 1; ifosfamide 1,200 mg/m2 on days 1-3; and cisplatin 20 mg/m2on days 1-3 (ITP). All pts received 4 X 3 weekly cycles with no significant toxicity. The first two patients underwent inguinal LND for pT3N2 (stage IIIB) disease followed by 4 cycles of ITP. In both patients surveillance imaging showed no evidence of disease recurrence 28 and 50 months, respectively, post completion of chemotherapy. The third patient underwent inguinal LND for pT1bN3 (stage IV) disease followed by 4 cycles of ITP. Surveillance imaging at 6 months post completion of chemotherapy showed no evidence of local or distant recurrence. Conclusions: Multimodality treatment of regional metastatic penile cancer offers the best chance of long-term disease-free and overall survival. The ITP regimen is relatively nontoxic and well-tolerated. We propose that this regimen should be further investigated in the adjuvant or peri-operative settings.